Company Filing History:
Years Active: 2008
Title: José Luis Fernández Puentes: Innovator in Antitumor Compounds
Introduction
José Luis Fernández Puentes is a notable inventor based in León, Spain. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antitumor compounds. His innovative work has led to the creation of a patent that showcases his expertise and dedication to advancing medical science.
Latest Patents
José Luis Fernández Puentes holds a patent for "Derivatives of variolin B." This invention provides antitumor compounds of formula (I), wherein R is an aromatic substituent. R can be hydrogen or a substituent when the dotted line is absent, or R is absent when the dotted line represents a bond to give a double bond between the nitrogen which bears R and the carbon which bears R. Additionally, R is an oxo group when the dotted line is absent or is a substituent when the dotted line represents a bond to give a double bond between the nitrogen bearing R and the carbon bearing R. R can also be hydrogen or a substituent, along with pharmaceutically acceptable salts thereof. This patent highlights his innovative approach to tackling cancer treatment.
Career Highlights
José Luis Fernández Puentes is associated with Pharma Mar, S.A., a company known for its focus on developing innovative medicines for cancer treatment. His work at Pharma Mar has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry. With a total of 1 patent, he has established himself as a key figure in the field.
Collaborations
Throughout his career, José has collaborated with talented professionals, including Mercedes Alvarez and David Fernández Bleda. These collaborations have fostered a creative environment that encourages innovation and the sharing of ideas.
Conclusion
José Luis Fernández Puentes is a distinguished inventor whose work in antitumor compounds has made a significant impact in the pharmaceutical industry. His dedication to innovation and collaboration continues to inspire advancements in cancer treatment.